Abstract
A nonnaturally occurring l-configuration nucleoside analog,l-β-5-bromovinyl-(2-hydroxymethyl)-1,3-(dioxolanyl)uracil (l-BVOddU) selectively inhibited varicella-zoster virus growth in human embryonic lung (HEL) 299 cell culture with an EC50 of 0.055 μM, whereas no inhibition of CEM and HEL 299 cell growth or mitochondrial DNA synthesis was observed at concentrations up to 200 μM. l-BVOddU was phosphorylated by viral thymidine kinase but not by human cytosolic thymidine kinase, and the antiviral activity of this compound is dependent on the viral thymidine kinase. Unlike other d-configuration bromovinyl deoxyuridine analogs, such as E-5-(2-bromovinyl)-2′-deoxyuridine and 1-β-arabinofuranosyl-E-5-(2-bromovinyl)uracil, this compound was metabolized only to its monophosphate metabolite. The di- or triphosphate metabolites were not detected. This suggested that the inhibitory mechanism may be unique and different from other anti-herpesvirus nucleoside analogs.
Footnotes
- Received May 12, 2000.
- Accepted July 18, 2000.
-
Send reprint requests to: Yung-chi Cheng, SHM-B 315, Department of Pharmacology, Yale University, New Haven, CT 06520. E-mail: Cheng_lab{at}yale.edu
-
This study was supported by National Institutes of Health grants CA 63477 and AI 33655. Y.-C. Cheng is a fellow of the National Foundation for Cancer Research.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|